Watch the replay of the "Living Well with Myeloma" Teleconference on CAR T-Cell Therapy

The next “Living Well with Myeloma” teleconference will focus on CAR T-Cell Therapy: What Myeloma Patients&Caregivers Need to Know. It takes place on Thursday, September 22, 2016 at 7 PM ET / 4 PM PT. Speakers are Dr. Rafat Abonour (Indiana Universityá Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania). CAR T cells, or chimeric antigen receptor T cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patient's T cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T cells are then reinfused into the body with the hope of fighting the disease. To learn about this exciting new therapy, register for free HERE. Pre-registration is highly recommended.
Source: International Myeloma Foundation - Category: Hematology Source Type: news

Related Links:

Authors: Nguyen Y, Stirnemann J, Belmatoug N Abstract Gaucher disease is a rare autosomal recessive genetic disease, caused by a deficiency of the lysosomal enzyme, glucocerebrosidase that leads to the accumulation of its substrate (glucosylceramide) in lysosomal macrophages. In the general population, its incidence varies between 0.4 and 5.8/100,000 inhabitants. Type 1 Gaucher disease is the most frequent and is characterized by its extreme heterogeneity including asymptomatic or more severe presentations. The most frequent symptoms are anemia, thrombocytopenia, splenomegaly, and/or hepatomegaly, and a potentially...
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
Swaminathan P. Iyer, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses Treatment Of T-Cell Compared To B-Cell Lymphoma. At T... Author: obr Added: 01/15/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Sattva Neelapu, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses Clinical Studies Examining Axicabtagene Ciloleucel. At The 60th ASH Annual Me... Author: obr Added: 01/15/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Nikhil Munshi, MD, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, discusses POLLUX &CAS... Author: obr Added: 01/15/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Nikhil Munshi, MD, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, discusses Outcomes Of ... Author: obr Added: 01/15/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Swaminathan P. Iyer, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, Discusses Improvements In The Treatment Of CTCL. At The 60th AS... Author: obr Added: 01/15/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Publication date: Available online 15 January 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hisham Moneib, Hanafy Hafez, Amr Abdalla, Omneya Hassanain., Leslie Lehmann, Alaa el HaddadAbstractRecovery of platelet count by day 100 post Hematopoietic Stem Cell Transplantation (HSCT) is affected by many factors and has been reported to be a predictor of overall survival in a variety of diseases and donor types. We investigated the correlation between day +100 platelet count and overall survival post allogeneic HSCT in a relatively homogeneous cohort of pediatric patients with hematological malignancies. We condu...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Swaminathan P. Iyer, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses Outcomes Of The ECHELON-2 Study. At The 60th ASH Annu... Author: obr Added: 01/14/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Sattva Neelapu, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses The Use Of Axicabtagene Ciloleucel With Elderly Lymphoma Patients. At The 60t... Author: obr Added: 01/14/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Nikhil Munshi, MD Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, discusses Outcomes Of T... Author: obr Added: 01/14/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Hematology | Immunotherapy | Learning | Myeloma | Universities & Medical Training | University of Pennsylvania